300725.SHE PharmaBlock Sciences Nanjing Inc Class A
- Market cap
- CNY 10.0B
- P/E
- 43.7x
- P/B
- 2.28x
- ROE
- 4.4%
- Dividend yield
- 0.66%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300725.SHE undervalued?
Graham number300725.SHE trades 110.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PharmaBlock Sciences Nanjing Inc Class A fundamental analysis
No fundamental analysis for PharmaBlock Sciences Nanjing Inc Class A yet.
PharmaBlock Sciences Nanjing Inc Class A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PharmaBlock Sciences Nanjing Inc Class A
PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial manufacturing in China and internationally. It offers medicinal chemistry-oriented SAR/SPR tool kits for molecule design; building blocks enabled libraries, including fragment-based drug discovery, and mega virtual library screening to support the discovery of novel hit compounds; custom synthesis (FFS); and full time equivalent…
Full company profilePharmaBlock Sciences Nanjing Inc Class A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PharmaBlock Sciences Nanjing Inc Class A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 188M | 273M | 478M | 662M | 1.02B | 1.20B | 1.59B | 1.73B | 1.69B | 1.97B | 2.18B |
| Gross Profit | 121M | 167M | 269M | 338M | 466M | 569M | 716M | 707M | 583M | 608M | 718M |
| Operating Income | 40.8M | 74.1M | 143M | 164M | 194M | 493M | 297M | 185M | 251M | 255M | 288M |
| EBITDA | 53.4M | 89.7M | 172M | 197M | 230M | 572M | 456M | 404M | 440M | 382M | 231M |
| Net Income | 36.1M | 67.2M | 133M | 152M | 184M | 487M | 314M | 197M | 220M | 184M | 202M |
| EPS | 0.27 | 0.47 | 0.72 | 0.82 | 0.98 | 2.44 | 1.57 | 0.98 | 1.10 | 0.79 | 0.86 |
| Balance Sheet | |||||||||||
| Total Assets | 299M | 567M | 761M | 1.03B | 2.43B | 3.51B | 4.86B | 5.10B | 4.94B | 7.34B | 5.44B |
| Total Liabilities | 45.0M | 63.8M | 161M | 288M | 531M | 879M | 2.20B | 2.27B | 1.95B | 1.04B | 849M |
| Shareholders' Equity | 245M | 495M | 600M | 741M | 1.89B | 2.43B | 2.66B | 2.83B | 2.99B | 6.30B | 4.59B |
| Cash & Short-term Investments | 78.1M | 158M | 266M | 185M | 1.35B | 1.00B | 1.31B | 1.60B | 756M | 533M | 693M |
| Total Debt | 3.80M | 299K | 25.2M | 60.4M | 120M | 381M | 1.57B | 1.75B | 1.36B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 22.8M | 54.6M | 160M | 127M | 272M | 238M | 247M | 247M | 303M | 667M | - |
| Capital Expenditure | 38.3M | 49.1M | 48.4M | 174M | 75.2M | 506M | 558M | 316M | 118M | 140M | 392M |
| Free Cash Flow | -15.5M | 5.58M | 112M | -46.5M | 196M | -268M | -311M | -68.9M | 185M | 527M | -56.7M |
| Ratios | |||||||||||
| ROE | 14.7% | 13.6% | 22.2% | 20.5% | 9.7% | 20.0% | 11.8% | 7.0% | 7.3% | 2.9% | 4.4% |
| ROA | 12.1% | 11.8% | 17.5% | 14.8% | 7.6% | 13.9% | 6.5% | 3.9% | 4.4% | 2.5% | 3.7% |
| Net Profit Margin | 19.2% | 24.6% | 27.9% | 23.0% | 18.0% | 40.5% | 19.7% | 11.4% | 13.0% | 9.3% | 9.3% |
| Debt to Equity | 0.02x | 0.00x | 0.04x | 0.08x | 0.06x | 0.16x | 0.59x | 0.62x | 0.46x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
PharmaBlock Sciences Nanjing Inc Class A dividends
- Dividend yield
- 0.66%
- Forward dividend
- 0.38 CNY
- Payout ratio
- 35.8%
- Ex-dividend date
- Aug 25, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 65.7M | 0.28 | 35.8% |
| 2024 | CNY 78.0M | 0.39 | 35.5% |
| 2023 | CNY 20.0M | 0.10 | 10.1% |
| 2022 | CNY 20.0M | 0.10 | 6.4% |
| 2021 | CNY 15.4M | 0.08 | 3.2% |
| 2020 | CNY 21.7M | 0.12 | 11.8% |
| 2019 | CNY 22.0M | 0.12 | 14.5% |
| 2018 | CNY 15.7M | 0.08 | 11.7% |
| 2017 | CNY 61.0K | 0.00 | 0.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on Apr 26, 2021.
Who owns PharmaBlock Sciences Nanjing Inc Class A
- Insiders 22.58%
- Institutions 2.55%
- Public & others 74.87%
- Shares outstanding 234M
- Free float 181M
PharmaBlock Sciences Nanjing Inc Class A company profile
- Company name
- PharmaBlock Sciences Nanjing Inc Class A
- Ticker
- 300725.SHE
- ISIN
- CNE1000035K5
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,593
- Fiscal year end
- December
- Address
- No. 81, Huasheng Road, Nanjing, China, 210032
- Phone
- 86 25 8691 8218
- Website
- pharmablock.com
About PharmaBlock Sciences Nanjing Inc Class A
PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial manufacturing in China and internationally. It offers medicinal chemistry-oriented SAR/SPR tool kits for molecule design; building blocks enabled libraries, including fragment-based drug discovery, and mega virtual library screening to support the discovery of novel hit compounds; custom synthesis (FFS); and full time equivalent (FTE). The company also provides small molecule drug substance CDMO services, including optimal route scouting; FFS and FTE for process research and development of RSMs, intermediates, and APIs; impurity studies and synthesis; solid state chemistry; analytical development and quality control; cGMP manufacturing of intermediates and APIs; and CMC regulatory filing support. In addition, it offers small molecule DP CDMO services, such as candidate screening and selection, early development, full development, registration, and post-approval; and new modality services, including target protein degrader, peptide, oligonucleotide, and ADC services. PharmaBlock Sciences (Nanjing), Inc. was founded in 2006 and is based in Nanjing, the People's Republic of China.
PharmaBlock Sciences Nanjing Inc Class A management
8- Dr. Minmin Yang Ph.D.Co-Founder, Chairman & CEO · born 1972
- Ms. Juanjuan WuCFO & Director · born 1977
- Mr. Shanbao YuSecretary of the Board · born 1982
- Dr. Shuhai Zhao Ph.D.Co-founder & Chief Scientific Officer · born 1963
- Dr. David Chen Ph.D.Executive VP, Chief Operation Officer & Head of CDMO
- Dr. Shijie Zhang Ph.D.Chief Technology Officer · born 1964
- Dr. Dezhi Sha Ph.D.Sr. VP of Process Technology & Manufacturing
- Dr. Jing Li Ph.D.Sr. VP of Process Chemistry & President of PharmaBlock (USA), Inc. · born 1973